

Sarah R Senum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5024097/publications.pdf>

Version: 2024-02-01

20
papers

753
citations

759233

12
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

673
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2018, 102, 832-844.	6.2	208
2	Polycystic Kidney Disease without an Apparent Family History. Journal of the American Society of Nephrology: JASN, 2017, 28, 2768-2776.	6.1	75
3	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62
4	Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1153-1161.	4.5	60
5	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
6	Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney International Reports, 2017, 2, 913-923.	0.8	42
7	The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight, 2020, 5, .	5.0	41
8	Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 69-79.	4.5	39
9	Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. Kidney International, 2020, 98, 476-487.	5.2	38
10	Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology Dialysis Transplantation, 2018, 33, 645-652.	0.7	31
11	The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. American Journal of Kidney Diseases, 2018, 72, 302-308.	1.9	29
12	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. European Journal of Human Genetics, 2021, 29, 760-770.	2.8	20
13	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. Kidney International Reports, 2021, 6, 2862-2884.	0.8	15
14	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
15	The genetic landscape of polycystic kidney disease in Ireland. European Journal of Human Genetics, 2021, 29, 827-838.	2.8	11
16	Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney International Reports, 2021, 6, 755-767.	0.8	10
17	Congenital Heart Disease in Adults with Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2022, 53, 316-324.	3.1	7
18	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease. <i>Kidney360</i> , 2022, 3, 465-476.	2.1	2
20	Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD. <i>Kidney International Reports</i> , 2022, 7, 1991-2005.	0.8	2